

PET/CT ONCOLOGY GUIDELINES - 2021
Medicare, Medicare Advantage, Medi-Cal, and Medi-Cal GMC

Disease Classification	CPT CODES	Initial Treatment Strategy	Subsequent Treatment Strategy
FDG PET		(PI modifier)	(PS modifier)
Brain, primary	78608 / A9552	Covered	Covered
Breast, female and male	78815 / A9552	Covered	Covered
Cervix	78815 / A9552	Covered	Covered
Colon and Rectum	78815 / A9552	Covered	Covered
Esophagus	78815 / A9552	Covered	Covered
Head and neck	78815 / A9552	Covered	Covered
Kaposi's sarcoma	78815 / A9552	Covered	Covered
Lung	78815 / A9552	Covered	Covered
Lymphoma	78815 / A9552 75816/ A9552	Covered	Covered
Melanoma of skin	78816 / A9552	Covered	Covered
Myeloma	78815 / A9552	Covered	Covered
Ovary	78815 / A9552	Covered	Covered
Pancreas	78815 / A9552	Covered	Covered
Prostate (FDG)	78815 / A9552	Not Covered	Covered
Testis	78815 / A9552	Covered	Covered
Thyroid	78815 / A9552	Covered	Covered
All other solid tumors	78815 / A9552	Covered	Covered
All other cancers not listed	78815 / A9552	Covered	Covered
SPECIALITY PET			
Prostate Recurrence w/ <i>Axumin</i> ¹	78815 / A9588	Not Covered	Covered
Neuroendocrine w/ <i>Dotatate</i> ²	78815 / A9587	Covered	Covered
Breast w/ <i>Cerianna</i> ³	78815 / A9591	Not Covered	Covered

¹*Axumin*® (*fluciclovine F 18*) is indicated for Positron Emission Tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

²*Gallium Ga 68 Dotatate* for localization of somatostatin receptor positive neuroendocrine tumors.

³*Cerianna* (*fluoroestradiol F18*)

FDG Brain PET is covered to differentiate FTD vs AD